Orasis Pharms Drug Patent Portfolio
Orasis Pharms owns 1 orange book drug protected by 4 US patents Given below is the list of Orasis Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10639297 | Ophthalmic pharmaceutical compositions and uses relating thereto | 18 Aug, 2037 | Active |
| US11129812 | Ophthalmic pharmaceutical compositions and uses relating thereto | 18 Aug, 2037 | Active |
| US11974986 | Ophthalmic pharmaceutical compositions and uses relating thereto | 18 Aug, 2037 | Active |
| US9867810 | Ophthalmic pharmaceutical compositions and uses relating thereto | 18 Aug, 2037 | Active |
Latest Legal Activities on Orasis Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Orasis Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 25 Oct, 2023 | US10639297 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 28 Sep, 2021 | US11129812 |
|
Recordation of Patent Grant Mailed
Critical
| 28 Sep, 2021 | US11129812 |
|
Email Notification
Critical
| 09 Sep, 2021 | US11129812 |
|
Issue Notification Mailed
Critical
| 08 Sep, 2021 | US11129812 |
|
Application Is Considered Ready for Issue
Critical
| 25 Aug, 2021 | US11129812 |
| Dispatch to FDC | 25 Aug, 2021 | US11129812 |
|
Mail Response to 312 Amendment (PTO-271)
Critical
| 24 Aug, 2021 | US11129812 |
|
Email Notification
Critical
| 24 Aug, 2021 | US11129812 |
|
Response to Amendment under Rule 312
Critical
| 19 Aug, 2021 | US11129812 |
|
Amendment after Notice of Allowance (Rule 312)
Critical
| 18 Aug, 2021 | US11129812 |
| Mail PUB other miscellaneous communication to applicant | 11 Aug, 2021 | US11129812 |
|
Email Notification
Critical
| 11 Aug, 2021 | US11129812 |
| PUB Other miscellaneous communication to applicant | 09 Aug, 2021 | US11129812 |
|
Issue Fee Payment Verified
Critical
| 27 Jul, 2021 | US11129812 |
Orasis Pharms's Family Patents
Orasis Pharms Drug List
Given below is the complete list of Orasis Pharms's drugs and the patents protecting them.
1. Qlosi
Qlosi is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10639297 | Ophthalmic pharmaceutical compositions and uses relating thereto |
18 Aug, 2037
(12 years from now)
| Active |
| US11129812 | Ophthalmic pharmaceutical compositions and uses relating thereto |
18 Aug, 2037
(12 years from now)
| Active |
| US11974986 | Ophthalmic pharmaceutical compositions and uses relating thereto |
18 Aug, 2037
(12 years from now)
| Active |
| US9867810 | Ophthalmic pharmaceutical compositions and uses relating thereto |
18 Aug, 2037
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qlosi's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List